Neoplastic Process
Corcept planning US, EU submissions for cortisol modulator after ovarian cancer win
Corcept, 130-nm albumin-bound paclitaxel
BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific
BNT327, BioNTech, month, BioNTech ‘s, Small cell carcinoma of lung, Pharmacotherapy
BioAtla lays off 30% of staff, hunts out partners for ADC and cancer antibody
Staff, Partner in relationship, CAB, BioAtla, 30%
Merck’s Injectable Keytruda Shows Promising Results in Pivotal Trial
Keytruda, subcutaneous injection, intravenous formula, non-small cell lung cancer, pivotal trial, Merck
FDA clears Exelixis’ TKI for neuroendocrine tumours
CABOMETYX, cabozantinib, neuroendocrine tumors, FDA approval, Exelixis, tyrosine kinase inhibitor
J&J combo signals new era in EGFR lung cancer with survival win against AstraZeneca’s Tagrisso
Continuance of life, Combined, Epidermal Growth Factor Receptor, Malignant neoplasm of lung, Overall Survival, Tagrisso
MacroGenics Discontinues Development of Vobra Duo ADC After Phase 2 Prostate Cancer Trial Results
MacroGenics, vobra duo, antibody-drug conjugate, B7-H3, prostate cancer, TAMARACK trial, discontinued development, safety concerns
Adaptimmune, after bringing cell therapy to market, questions viability and defunds 2 preclinical programs
Adaptimmune, Tecelra, Viable, Market, Solid Neoplasm, cellular targeting
Elevation Oncology Discontinues Lead Drug and Cuts Workforce
EO-3021, Claudin 18.2 ADC, Phase 1 trial, gastric cancer, layoffs, strategic options
Roche continues ADC dealmaking spree with $1B biobucks pact with Oxford BioTherapeutics
OBT, therapeutic autologous dendritic cells, Roche (company), Partnership, Oxford BioTherapeutics, Antibody-Drug Conjugates, biobucks, New